Peer-Reviewed Journal Details
Mandatory Fields
O'Connor, EM,Grealy, G,McCarthy, J,Desmond, A,Craig, O,Shanahan, F,Cashman, KD
2014
October
British Journal of Nutrition
Effect of phylloquinone (vitamin K-1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
Validated
Optional Fields
Phylloquinone (vitamin K-1) Percentage of undercarboxylated osteocalcin Bone health indices Intervention studies Crohn's disease INFLAMMATORY-BOWEL-DISEASE SERUM UNDERCARBOXYLATED OSTEOCALCIN POSTMENOPAUSAL WOMEN BIOCHEMICAL INDEXES CONTROLLED-TRIAL MINERAL DENSITY HIP FRACTURE RISK OSTEOPOROSIS TURNOVER
112
1163
1174
Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K-1). By conducting two RCT, the present study aimed to first establish whether suppl(e)mentation with 1000 mg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 mu g of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 mu g vitamin K/d (both coadministered with Ca (500mg/d) and vitamin D-3 (10 mu g/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47%, and this was suppressed upon supplementation with 1000 mu g of phylloquinone daily (-81%; P < 0.01) and not suppressed further by 2000 mu g of phylloquinone daily. Compared with the placebo, supplementation with 1000 mu g of phylloquinone daily for 12 months had no significant effect (P > 0.1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P < 0.05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000mg of phylloquinone daily (with Ca and vitamin D-3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency. British Journal of Nutrition
10.1017/S0007114514001913
Grant Details